Skip to main content
Erschienen in: Journal of Nephrology 1/2014

01.02.2014 | Original Article

Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension

verfasst von: Farahnak Assadi

Erschienen in: Journal of Nephrology | Ausgabe 1/2014

Einloggen, um Zugang zu erhalten

Abstract

Background

Essential hypertension is frequently associated with hyperuricemia in both adult and pediatric patients. Lowering serum uric acid level may provide greater benefit than simply treating hypertension.

Patients and methods

Forty-four adolescents, aged 12–19 years, newly diagnosed as essential hypertension (secondary hypertension was excluded) and previously untreated were randomized (open label trial) to receive either enalapril or enalapril plus allopurinol in combination. All participants had baseline serum uric acid level ≥5.5 mg/dl.

Results

Baseline mean blood pressure (BP), age and body mass index were similar between the two groups. After 8 weeks’ treatment, BP reduction was greater, percent of treatment group achieving target BP level was greater, and serum uric acid level was lower in the combination treatment group. There were no adverse effects during the course of therapy.

Conclusion

Results suggest that uric acid reduction may be used as adjunctive antihypertensive therapy in hypertensive adolescents with hyperuricemia while closely monitoring for any adverse effect.
Literatur
2.
Zurück zum Zitat Grayson PC, Kim SY, Lavalley M, Choi HK (2011) Hyperuricemia and incidence hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRef Grayson PC, Kim SY, Lavalley M, Choi HK (2011) Hyperuricemia and incidence hypertension: a systematic review and meta-analysis. Arthritis Care Res 63:102–110CrossRef
3.
Zurück zum Zitat Shankar A, Klein R, Klein BE, Nieto FJ (2006) The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 20:937–945PubMedCrossRef Shankar A, Klein R, Klein BE, Nieto FJ (2006) The association between serum uric acid level and long-term incidence of hypertension: population-based cohort study. J Hum Hypertens 20:937–945PubMedCrossRef
4.
Zurück zum Zitat Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303PubMedCrossRef Krishnan E, Kwoh CK, Schumacher HR, Kuller L (2007) Hyperuricemia and incidence of hypertension among men without metabolic syndrome. Hypertension 49:298–303PubMedCrossRef
5.
Zurück zum Zitat Loeffler LF, Navas-Acien A, Brady TM, Miller ER 3rd, Fadrowski JJ (2012) Uric acid level and elevated blood pressure in US adolescents. National Health and Nutrition Examination Survey, 1999–2006. Hypertension 59:811–817PubMedCentralPubMedCrossRef Loeffler LF, Navas-Acien A, Brady TM, Miller ER 3rd, Fadrowski JJ (2012) Uric acid level and elevated blood pressure in US adolescents. National Health and Nutrition Examination Survey, 1999–2006. Hypertension 59:811–817PubMedCentralPubMedCrossRef
6.
Zurück zum Zitat Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P (2000) Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36:1072–1078PubMedCrossRef Verdecchia P, Schillaci G, Reboldi G, Santeusanio F, Porcellati C, Brunetti P (2000) Relation between serum uric acid and risk of cardiovascular disease in essential hypertension. The PIUMA study. Hypertension 36:1072–1078PubMedCrossRef
8.
Zurück zum Zitat Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932PubMedCentralPubMedCrossRef Feig DI, Soletsky B, Johnson RJ (2008) Effect of allopurinol on blood pressure of adolescents with newly diagnosed essential hypertension: a randomized trial. JAMA 300:924–932PubMedCentralPubMedCrossRef
9.
Zurück zum Zitat Kanabay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al (2011) A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6:1887–1894CrossRef Kanabay M, Huddam B, Azak A, Solak Y, Kadioglu GK, Kirbas I et al (2011) A randomized study of allopurinol on endothelial function and estimated glomerular filtration rate in asymptomatic hyperuricemic subjects with normal renal function. Clin J Am Soc Nephrol 6:1887–1894CrossRef
10.
Zurück zum Zitat Soletsky B, Feig DI (2012) Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60:1148–1156PubMedCrossRef Soletsky B, Feig DI (2012) Uric acid reduction rectifies prehypertension in obese adolescents. Hypertension 60:1148–1156PubMedCrossRef
11.
Zurück zum Zitat Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ (2013) Uric acid and the origins of hypertension. J Pediatr 162:896–902PubMedCrossRef Feig DI, Madero M, Jalal DI, Sanchez-Lozada LG, Johnson RJ (2013) Uric acid and the origins of hypertension. J Pediatr 162:896–902PubMedCrossRef
12.
Zurück zum Zitat Feig DI (2012) The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens 14:346–352CrossRef Feig DI (2012) The role of uric acid in the pathogenesis of hypertension in the young. J Clin Hypertens 14:346–352CrossRef
13.
Zurück zum Zitat Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, Johnson RJ (2010) Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 12:108–117PubMedCrossRef Mazzali M, Kanbay M, Segal MS, Shafiu M, Jalal D, Feig DI, Johnson RJ (2010) Uric acid and hypertension: cause or effect? Curr Rheumatol Rep 12:108–117PubMedCrossRef
14.
Zurück zum Zitat Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101–1106PubMedCrossRef Mazzali M, Hughes J, Kim YG, Jefferson JA, Kang DH, Gordon KL et al (2001) Elevated uric acid increases blood pressure in the rat by a novel crystal-independent mechanism. Hypertension 38:1101–1106PubMedCrossRef
15.
Zurück zum Zitat Assadi F (2007) Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol 29:580–589PubMedCrossRef Assadi F (2007) Relation of left ventricular hypertrophy to microalbuminuria and C-reactive protein in children and adolescents with essential hypertension. Pediatr Cardiol 29:580–589PubMedCrossRef
16.
Zurück zum Zitat National high Blood Pressure Evaluation Program Working Group on High Blood Pressure on Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef National high Blood Pressure Evaluation Program Working Group on High Blood Pressure on Children and Adolescents (2004) The fourth report on the diagnosis, evaluation, and treatment of high blood pressure in children and adolescents. Pediatrics 114:555–576CrossRef
17.
Zurück zum Zitat Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60PubMedCrossRef Ogden CL, Kuczmarski RJ, Flegal KM, Mei Z, Guo S, Wei R (2002) Centers for Disease Control and Prevention 2000 growth charts for the United States: improvements to the 1977 National Center for Health Statistics version. Pediatrics 109:45–60PubMedCrossRef
18.
Zurück zum Zitat Foreman JP, Choi H, Curhan GC (2007) Plasma uric acid level for incident hypertension among men. J Am Soc Nephrol 18:287–292CrossRef Foreman JP, Choi H, Curhan GC (2007) Plasma uric acid level for incident hypertension among men. J Am Soc Nephrol 18:287–292CrossRef
19.
Zurück zum Zitat Crom WR, Webster SL, Bobo L, Teresi ME, Relling MV, Evans WE (1987) Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 41:645–650PubMedCrossRef Crom WR, Webster SL, Bobo L, Teresi ME, Relling MV, Evans WE (1987) Simultaneous administration of multiple model substrates to assess hepatic drug clearance. Clin Pharmacol Ther 41:645–650PubMedCrossRef
20.
Zurück zum Zitat Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH et al (2004) Uric acid and the state of the intrarenal renin–angiotensin system in humans. Kidney Int 66:1465–1470PubMedCrossRef Perlstein TS, Gumieniak O, Hopkins PN, Murphey LJ, Brown NJ, Williams GH et al (2004) Uric acid and the state of the intrarenal renin–angiotensin system in humans. Kidney Int 66:1465–1470PubMedCrossRef
21.
Zurück zum Zitat Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef Khosla UM, Zharikov S, Finch JL, Nakagawa T, Roncal C, Mu W, Krotova K (2005) Hyperuricemia induces endothelial dysfunction. Kidney Int 67:1739–1742PubMedCrossRef
22.
Zurück zum Zitat Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 26:269–275PubMedCrossRef Corry DB, Eslami P, Yamamoto K, Nyby MD, Makino H, Tuck ML (2008) Uric acid stimulates vascular smooth muscle cell proliferation and oxidative stress via the vascular renin–angiotensin system. J Hypertens 26:269–275PubMedCrossRef
23.
Zurück zum Zitat Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17:1466–1471PubMedCrossRef Zoccali C, Maio R, Mallamaci F, Sesti G, Perticone F (2006) Uric acid and endothelial dysfunction in essential hypertension. J Am Soc Nephrol 17:1466–1471PubMedCrossRef
24.
Zurück zum Zitat Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221–226PubMedCrossRef Farquharson CA, Butler R, Hill A, Belch JJ, Struthers AD (2002) Allopurinol improves endothelial dysfunction in chronic heart failure. Circulation 106:221–226PubMedCrossRef
25.
Zurück zum Zitat Sánchez-Lozada LG, Tapia E, Soto V, Ávila-Casado C, Franco M, Zhao L, Johnson RJ (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23:1179–1185PubMedCrossRef Sánchez-Lozada LG, Tapia E, Soto V, Ávila-Casado C, Franco M, Zhao L, Johnson RJ (2008) Treatment with the xanthine oxidase inhibitor febuxostat lowers uric acid and alleviates systemic and glomerular hypertension in experimental hyperuricaemia. Nephrol Dial Transplant 23:1179–1185PubMedCrossRef
26.
Zurück zum Zitat Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114PubMedCentralPubMedCrossRef Pacher P, Nivorozhkin A, Szabo C (2006) Therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. Pharmacol Rev 58:87–114PubMedCentralPubMedCrossRef
27.
Zurück zum Zitat Mclnnes GT, Lawson DH, Jick H (1981) Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 40:245–249CrossRef Mclnnes GT, Lawson DH, Jick H (1981) Acute adverse reactions attributed to allopurinol in hospitalized patients. Ann Rheum Dis 40:245–249CrossRef
Metadaten
Titel
Allopurinol enhances the blood pressure lowering effect of enalapril in children with hyperuricemic essential hypertension
verfasst von
Farahnak Assadi
Publikationsdatum
01.02.2014
Verlag
Springer International Publishing
Erschienen in
Journal of Nephrology / Ausgabe 1/2014
Print ISSN: 1121-8428
Elektronische ISSN: 1724-6059
DOI
https://doi.org/10.1007/s40620-013-0009-0

Weitere Artikel der Ausgabe 1/2014

Journal of Nephrology 1/2014 Zur Ausgabe

Leitlinien kompakt für die Innere Medizin

Mit medbee Pocketcards sicher entscheiden.

Seit 2022 gehört die medbee GmbH zum Springer Medizin Verlag

Erhebliches Risiko für Kehlkopfkrebs bei mäßiger Dysplasie

29.05.2024 Larynxkarzinom Nachrichten

Fast ein Viertel der Personen mit mäßig dysplastischen Stimmlippenläsionen entwickelt einen Kehlkopftumor. Solche Personen benötigen daher eine besonders enge ärztliche Überwachung.

Nach Herzinfarkt mit Typ-1-Diabetes schlechtere Karten als mit Typ 2?

29.05.2024 Herzinfarkt Nachrichten

Bei Menschen mit Typ-2-Diabetes sind die Chancen, einen Myokardinfarkt zu überleben, in den letzten 15 Jahren deutlich gestiegen – nicht jedoch bei Betroffenen mit Typ 1.

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Update Innere Medizin

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.